HTG Molecular Diagnostics Inc (HTGMQ) 股息

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. The company is headquartered in Tucson, Arizona and currently employs 53 full-time employees. The company went IPO on 2015-05-06. The firm is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The firm's Gene Expression Panels include HTG Research Use Only (RUO) Panels and HTG EdgeSeq Research Use Only (RUO) Panels, such as the HTG Transcriptome Panel, HTG EdgeSeq miRNA Whole Transcriptome Assay, HTG EdgeSeq Oncology Biomarker Panel, HTG EdgeSeq Precision Immuno-Oncology Panel, HTG EdgeSeq Immune Response Panel, HTG EdgeSeq Pan B-Cell Lymphoma Panel, HTG EdgeSeq Mouse mRNA Tumor Response Panel, and HTG EdgeSeq DLBCL Cell of Origin Assay. The HTG EdgeSeq system provides gene expression profiling for researchers, laboratory staff, and biomarker leads in discovery, translational medicine, and oncology applications. VERI/O Laboratory Services is a molecular lab providing gene expression profiling results.